Shots:
- DUALITYBIO has entered into a collaboration & license agreement with Genentech to develop next-generation ADCs, leveraging DUALITYBIO’s DUPAC (DualityBio Unique Payload Antibody Conjugate) platform
- DualityBio will discover & develop ADCs against Genentech-selected oncology targets using DUPAC payloads, leading discovery & early global development, while Genentech will secure exclusive global rights & take over development & commercialization after P-Ia
- DualityBio will receive ~$45M upfront & >$1B in development, regulatory & commercial milestones across all programs, along with tiered royalties on annual net sales of approved products
Ref: PRnewswire | Image: DualityBio & Genentech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
